Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.

Dr. Greg Shay is a pediatric pulmonologist, a children's lung specialist, with the NGO MedGlobal who has just returned from a ...

The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

Oct. 30, 2024 — In the face of increased human pressures and climate change, a team of scientists have launched a new online tool to assist marine managers and restoration experts to bolster the ...

Purdue University’s College of Science is committed to the persistent pursuit of the mathematical and scientific knowledge that forms the very foundation of innovation. More than 340 tenure-track ...

Lenacapavir's manufacturer Gilead has signed deals with six companies—in Egypt, India, Pakistan, and the USA—to sell generic lenacapavir in 120 low-income and lower-middle-income countries. Until ...

(RTTNews) - According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent reduced risk of HIV infection overall. The Phase III ...